|
Authored by:
- AdventHealth Research Institute
|
Estimated read time:
In this episode, Dr. Richard Pratley, Medical Director at AdventHealth Diabetes Institute, discusses a groundbreaking study on Ozempic. Dr. Pratley shares insights from the global FLOW study, highlighting Ozempic's potential to reduce chronic kidney disease.
Recent News
-
News
Metabolic dysfunction associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), affects about 70% of people with type 2 diabetes, placing them at...
-
News
Dr. Kirk Erickson Joins the NavNeuro Podcast to Discuss the Connection Between Physical Activity and Brain Health
-
News
Results From IGNITE Research Study Published in the Medical Journal "Age and Ageing"